SANDIPIPER studies the combination of taselisib plus fulvestrant in patients with ER positive, HER2 negative locally advanced or metastatic BC enriched for patients with PIK3CA mutant tumors [133]. This evidence concerns the gene ERBB2 and breast cancer.